Seiichi Kato

Professor

Saga University
Country flagJapan

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (16)

Year:

2026

Year:

2026

Year:

2026

The 5th edition of the WHO classification of haematolymphoid tumours introduces the concept of hyperplasias arising in immune deficiency and dysregulation (IDD), which are frequently associated with Epstein-Barr virus (EBV). These lesions can be histologically classified as follicular hyperplasia (FH), infectious mononucleosis-like hyperplasia (IMH), or plasmacytic hyperplasia. Although EBV-associated reactive lymphoid hyperplasia (EBV-RLH) has been recognized in various IDD settings, comprehensive clinicopathologic analyses remain limited. We analyzed 34 Japanese patients with EBV-RLH. The IDD settings primarily included autoimmune diseases (with or without immunosuppressive therapy), chemotherapy for prior malignancies, aging, post-hematopoietic stem cell transplantation, and HIV infection. No patient exhibited histologic transformation or died due to EBV-RLH. Three patients had concurrent hematologic malignancies, and 12 had immune dysregulation related to prior chemotherapy. Histologically, 20 cases showed FH, 6 IMH, and 8 nonspecific patterns. EBER-positive cells were distributed in both interfollicular areas and germinal centers (GCs) in 27 cases (79%) and confined to interfollicular areas in 7. Six cases exhibited intensive aggregation of EBER-positive cells in one or a few GCs. Double staining confirmed that most EBER-positive cells expressed CD79a but not CD3. IGH and TCRG PCR analyses were successful in 24 cases: 21 were negative for both rearrangements, and 3 showed clonal rearrangements (1 double, 1 IGH-only, and 1 TCRG-only). EBV-RLH generally followed an indolent course; however, it may coexist with hematologic malignancies or develop after multichemotherapy. Careful histopathologic evaluation is essential to avoid overlooking concurrent malignancy or unnecessary treatment.

Year:

2026

Year:

2026

Epstein-Barr virus (EBV) infects >90% of humans and is associated with both hematological and epithelial malignancies. Here, we analyzed 990 EBV genomes (319 newly sequenced and 671 from public databases) from patients with various diseases to comprehensively characterize genomic variations, including single nucleotide variations (SNVs) and structural variations (SVs). Although most SNVs were a result of conservative evolution and reflected the geographical origins of the viral genomes, we identified several convergent SNV hot spots within the central homology domain of EBNA3B, the transactivation domain of EBNA2, and the second transmembrane domain of LMP1. These convergent SNVs seem to fine-tune viral protein functionality and immunogenicity. SVs, particularly large deletions, were frequently observed in chronic active EBV disease (28%), EBV-positive diffuse large B-cell lymphoma (48%), extranodal natural killer/T-cell lymphoma (41%), and Burkitt lymphoma (25%), but were less common in infectious mononucleosis (11%), posttransplant lymphoproliferative disorder (7%), and epithelial malignancies (5%). In hematological malignancies, deletions often targeted viral microRNA clusters, potentially promoting viral reactivation and lymphomagenesis. Nondeletion SVs, such as inversions, were also prevalent, with several inversions disrupting the C promoter to suppress latent gene expression, thereby maintaining viral dormancy. Furthermore, recurrent EBNA3B deletions suggested that this viral transcription factor functions as a tumor suppressor. EBNA3B knockout experiments in vitro revealed downregulation of human tumor suppressors, including PTEN and RB1, which could explain the enhanced lymphomagenesis observed in EBNA3B-deficient lymphoblastoid cell line xenografts. Our findings highlight both disease-specific and general contributions of EBV genomic alterations to human cancers, particularly in hematological malignancies.

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Collaborators (20)

Kikkeri N Naresh

Section Head of Pathology & Professor

University of Washington

UNITED STATES
View details

Javeed Iqbal

Professor, Odeth E. Wall Centennial Professor of Oncology

University of Nebraska Medical Center

UNITED STATES
View details

Chris Bacon

Clinical Senior Lecturer/Consultant

Newcastle University

UNITED KINGDOM
View details

Kieron Dunleavy

Director

Georgetown University

UNITED STATES
View details

Lorenzo Leoncini

Docenti di ruolo di Ia fascia

University of Siena

ITALY
View details

Brian Walker

Professor

University of Miami

UNITED STATES
View details

Pedro Farinha

Clinical Professor

The University of British Columbia

CANADA
View details

Catalina Amador

Professor of Pathology

University of Miami Health System

UNITED STATES
View details

John Choi

The University of Alabama

UNITED STATES
View details

Hiroshi Kimura

Nagoya University

JAPAN
View details

Masamitsu Yanada

Nagoya University Hospital

JAPAN
View details

Jun-ichi Kawada

Professor

Fujita Health University

JAPAN
View details

Taiichi Wakiya

Lecture

Jichi Medical University

JAPAN
View details

Reuben M. Tooze

Professor

University of Leeds

UNITED KINGDOM
View details

Masato Nakaguro

Nagoya University Hospital

JAPAN
View details

Yuka Torii

Lecturer, MD, PhD

Nagoya University

JAPAN
View details

Sarah E. Coupland

Personal Chair

University of Liverpool

UNITED KINGDOM
View details

Davide Rossi

Associate Professor of Medicine

Università della Svizzera Italiana (USI)

SWITZERLAND
View details

Vaskar Saha

The University of Manchester

UNITED KINGDOM
View details

Yusuke Okuno

Nagoya University Graduate School of Medicine

JAPAN
View details